Advertisement
Niravam, Parcopa and Kemstro are central nervous system ("CNS") products.Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for themanagement of severely ill schizophrenic patients who fail to respondadequately to standard schizophrenia drug treatments. FazaClo is supplied asan innovative orally disintegrating tablet that uses proprietary formulationtechnologies licensed from CIMA Labs Inc. ("CIMA"), a subsidiary of CephalonInc (NASDAQ: CEPH).
Advertisement
Mr Seamus Mulligan, Chairman and Chief Executive of Azur stated, "We arepleased to add these valuable products to our portfolio. In particular,Niravam, Parcopa and Kemstro represent a broadening of our CNS franchise andare consistent with our approach of improving our products through theapplication of value added drug delivery technologies."
Niravam and Parcopa have been commercially available in the U.S. since2005 and 2004, respectively. There is one approved generic competitor toParcopa. Two ANDAs to Niravam have been filed with the FDA. Kemstro andFluxid are both FDA approved but not yet commercially available in the U.S.
About Azur Pharma
Azur is a privately held pharmaceutical company dedicated to enhancingpatients' lives by developing and marketing pharmaceutical products inspecialist therapeutic areas. Azur's strategy is to identify, evaluate,selectively acquire and enhance the value of late stage development andapproved pharmaceutical products. (Website: http://www.azurpharma.com )
SOURCE Azur Pharma Limited
